Sorry BT...I have to disagree with you
Have a look around mate....practically every biotech on the market has substantially re-rated...biotechs behind DXB in terms if trials..CYP, PAB, ACW, BXN and the list goes on
And DXB has still managed to attract zero interest, zero volume and zero tangible rise in value
How you and others can see this as the '' dream team'' and '' a management team for which we should feel blessed'' absolutely amazes me....it flies in the face of every bit of tangible evidence we have
They have had plenty of time....my report card is a '' Fail''
Sorry BT...I have to disagree with you Have a look around...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.025(6.67%) |
Mkt cap ! $25.68M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 35.0¢ | $387.8K | 1.079M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 394907 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 15948 | 1 |
View Market Depth
| Last trade - 16.10pm 12/12/2024 (20 minute delay) ? |
| DXB (ASX) Chart |